Showing 2644 results
- Media Release /Approval is based on pivotal Phase II study in which objective response rate (ORR) in patients with laBCC was 58%; responses were durable[1] Basal cell carcinoma, the most common form of skin…
- Media Release /CHMP positive opinion for EU approval of Tafinlar and Mekinist combination in BRAF V600 mutation-positive melanoma, the most aggressive type of skin cancer FDA grants priority review for…
- Media Release /Agreement gives Novartis access to four pre-clinical programs that target regulatory T cell populations, inhibitory cytokines, and immunosuppressive metabolites in the tumor microenvironment…
- Media Release /The Breezhaler(TM) inhaler is the device for Novartis' portfolio of COPD treatments of Onbrez and Seebri, and Ultibro, the leading LABA/LAMA treatment The collaboration further supports Novartis'…
- Media Release /Cosentyx (secukinumab) is the first IL-17A inhibitor approved in Europe to treat ankylosing spondylitis (AS) and first treatment advance in 16 years since anti-tumor necrosis factor (anti-TNF)…
- Media Release /Coartem® Dispersible*, the first WHO prequalified[1] pediatric antimalarial treatment, has become the standard of care in over 30 malaria-endemic countries Since 2009, Novartis has supplied 300…
- Media Release /Cosentyx is the first and only interleukin-17A (IL-17A) inhibitor approved for adult patients with ankylosing spondylitis (AS) and psoriatic arthritis (PsA) FDA approval for Cosentyx is…
Pagination
- ‹ Previous page
- 1
- …
- 157
- 158
- 159
- 160
- 161
- 162
- 163
- …
- 265
- › Next page